Show summary Hide summary
Connecticut this week moved to block retail sales of a little-known antidepressant that health officials say has been repackaged and sold as a recreational opioid-like product, part of a wider push by states to tighten controls on the substance. The change follows warnings from federal regulators who call the trend a growing public-health concern, especially for young people and those with substance-use disorders.
Why authorities are acting now
Known in medical circles as tianeptine, the compound is legally prescribed in some countries but has appeared in the U.S. market in pills, powders, salts and liquids marketed for pain relief, mood or energy. Regulators and emergency physicians say misuse can produce euphoria and, at higher doses, can depress breathing in ways similar to powerful opioids.
China clamps down on AI companions: users scramble as services disappear
Cleveland signs Mario Hezonja: unmistakable shift in post-LeBron era
The U.S. Food and Drug Administration and the Drug Enforcement Administration have both signaled alarm. In recent weeks FDA leadership described the pattern of retail availability and flavored formulations as a mounting health risk. The DEA has documented overdoses linked to the substance and warned it can cause severe sedation and respiratory failure.
How many states have moved and what Connecticut did
Fourteen states have now placed tianeptine on a Schedule I-style list or otherwise restricted its sale. Connecticut became the latest to finalize a ban on commercial distribution, effective this week, adding the drug to a list that also now includes plant- and synthetic-derived substances targeted by the state.
- Legal status: 14 states have adopted Schedule I classifications or bans; Connecticut’s action takes effect immediately.
- Retail presence: Products have been sold at convenience stores, gas stations, vape shops and online marketplaces.
- Brand names: Street and retail labels include names such as Tianaa, ZaZa, Neptune’s Fix, Pegasus and TD Red.
- Health risks: Euphoria at low doses; opioid-like respiratory depression at higher doses; documented cases of addiction and overdose.
- Testing gaps: These products are often not screened for in routine toxicology, complicating overdose investigations.
How it’s marketed and why that’s dangerous
Retail versions are frequently presented with colorful packaging and candy-like flavors, a combination officials say can mask the actual risks and appeal to younger consumers. Some sellers advertise the product as a cure for anxiety, depression or chronic pain, though the FDA has not approved such over-the-counter uses.
Because formulations vary, potency can be unpredictable. Physicians say that while small amounts may boost serotonin activity, escalating doses can engage the brain’s mu-opioid receptors—raising the risk of tolerance, dependence and life-threatening respiratory depression.
Related substances added in Connecticut’s update
The state’s scheduling action didn’t stop with tianeptine. Connecticut also listed kratom’s active alkaloid 7-hydroxymitragynine, along with other compounds such as Bromazolam, Flubromazolam, Nitazenes and Phenibut, citing addiction and overdose concerns.
Public health officials note that 7-hydroxymitragynine is especially potent at opioid receptors and has been linked to overdoses. The absence of FDA approval for these products amplifies the urgency for oversight, they say.
Voices from regulators and clinicians
Federal and state officials have urged swift action. FDA leadership described the retail spread of these products as a “dangerous and growing” trend and emphasized the particular danger to adolescents and people in recovery from substance use.
Clinicians with experience treating overdoses explain the mechanism differently depending on dose: early serotonergic effects may give way to potent opioid receptor stimulation as intake increases, culminating in slowed breathing and possible cardiac arrest.
What this means for consumers
If you or someone you know uses products marketed under unfamiliar names for mood, pain or alertness, be aware they may contain unregulated psychoactive ingredients and carry a risk of dependence or overdose.
- Watch for signs of overdose — shallow or stopped breathing, severe sedation, loss of consciousness — and call emergency services immediately.
- Inform clinicians and emergency responders about any retail supplements or powders used; standard toxicology may not detect these substances.
- Check local regulations: bans and scheduling vary by state and may change quickly.
Regulators say the pattern of retail availability and inconsistent labeling creates a public-health gap that requires both local enforcement and broader federal attention. Until testing and oversight become routine, clinicians and consumers will likely continue to confront unexpected cases linked to these products.
